Daniel L Reisner

IAM Research

The Patent 1000 focuses exclusively on patent practice and has firmly established itself as the definitive 'go-to' resource for those seeking world-class legal patent expertise.

Silver - Individuals: litigation

For legal market watchers it has been exciting to see Arnold & Porter’s success in the courtroom over recent years; it has put in resonant performances for innovation leaders in disputes that really matter at a technical, legal and business level. Essential to this story are the contributions of New Yorkers David Barr, Daniel DiNapoli, Aaron Stiefel and Dan Reisner, who have a vast amount of collective experience. Barr has written headlines recently with a win for Sanofi and Regeneron in district court litigation and at the Federal Circuit in a re-trial and appeal of an action brought by Amgen to determine the validity of patents involving his clients’ cholesterol-reducing drug Praluent. “David is deeply knowledgeable about the issues in complex cases and is extremely thorough in his work and analysis, which he completes in good time and within budget. He is very accessible and provides relevant advice beyond the scope of the projects he is retained for.” DiNapoli and Stiefel, meanwhile, have been representing Pfizer in Hatch-Waxman litigations in defence of blockbuster products under its Xeljanz brand. The firm has a longstanding relationship with Pfizer and has produced sterling results relating to many of its products, including Viagra and Celebrex, in much of which Reisner has also been involved. Reisner is a dynamic trial lawyer with skills, knowledge and experience cutting across life sciences and tech.

Get unlimited access to all IAM content